

To

November 14, 2025

The Listing Department
Bombay Stock Exchange Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 532771

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Mumbai – 400051

Trading Symbol: JHS

Subject: Outcome of the Board Meeting held on Friday, November 14, 2025

Ref.: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Dear Sir,

In terms of above referred provisions, this is to inform that the Board of Directors of the Company at their meeting held on **Friday, November 14, 2025**, inter-alia considered and approved the following businesses:

- Un-Audited Financial Results for the Quarter and half year ended September 30, 2025, duly reviewed and recommended by the Audit Committee and took note of the Limited review reports issued by the Statutory Auditors on the said results.

Enclosed are the following documents in respect of the items transacted in the meeting:

1. The Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th, September, 2025. (Annexure-A)
2. Limited Review Reports on Financial Results (Standalone and Consolidated) issued by M/s V.K. Khosla & Co., Chartered Accountants, the Statutory Auditors. (Annexure-B)

The Board Meeting commenced at 12:21 P.M. and concluded at 3:10 P.M. This information shall be made available on the website of the Company viz., www.svendgaard.com.

Kindly take the same on records.

**Thanking You,
For JHS Svendgaard Laboratories Limited**

**Komal Jha
Company Secretary & Compliance officer
Encl: A/a**



Independent Auditor's Review Report on Unaudited standalone Quarterly Financial Results and Year to Date Financial Results of JHS Svendgaard Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

**To the Board of Directors of
JHS Svendgaard Laboratories Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results ('the Statement') of JHS Svendgaard Laboratories Limited ('the Company') for the **quarter ended 30 September 2025** and **year to date financial results for the period 01 April 2025 to 30 September 2025**, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial results are free of material misstatements. A review of interim financial information consists of making inquiries primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. **Emphasis of Matter**

There is no Emphasis of Matter in the report for the quarter ended September 30, 2025.

6. **Other Matters**

The standalone financial results/statements for the quarter and half year ended September 30, 2024 presented in the accompanying standalone financial results were reviewed by the predecessor auditor who expressed unmodified opinion vide their report dated November 13, 2024. The aforesaid financial information/ results/ statements were furnished to us by the management and has been relied upon for the purpose of review of accompanying statement.

Our conclusion is not modified in respect of above matters.

For V.K. Khosla & Co.
Chartered Accountants
FRN 002283N


Amit Khosla
(Partner)

Memb No. 095943

UDIN: 25095943 BMJT RV7823



Place: New Delhi

Date: November 14, 2025

JHS SVENDGAARD LABORATORIES LIMITED
Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahan, Distt. Sirmour, Himachal Pradesh - 173030, India
CIN: 174110HP2004PLC027558

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF ENDED 30 SEPTEMBER 2025

(Rs. in lakhs)

S.No.	Particulars	Quarter Ended 30 September 2025	Quarter Ended 30 Jun 2025	Quarter Ended 30 September 2024	Half Year Ended 30 September 2025	Half Year Ended 30 September 2024	Year Ended 31 March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Revenue from operations	2,227.71	2,345.41	1,968.07	4,573.12	4,416.46	9,199.73
	Other income	113.84	99.83	86.09	213.67	118.09	287.71
	Total income	2,341.56	2,445.24	2,054.16	4,786.80	4,534.55	9,487.44
2	Expenses						
	Cost of materials consumed	1,294.62	1,421.83	1,239.20	2,716.45	2,718.05	5,745.75
	Purchases of stock-in-trade	85.79	9.72	20.33	95.50	112.72	308.19
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(66.48)	(41.64)	53.84	(108.12)	(83.65)	50.28
	Employee benefits expense	269.01	266.53	264.81	535.54	516.50	1,011.63
	Finance costs	20.09	15.67	10.52	35.76	22.20	56.50
	Depreciation and amortisation expenses	186.13	187.61	198.07	373.74	395.30	795.02
	Other expenses	553.88	522.70	474.58	1,076.57	1,040.61	2,484.30
	Total expenses	2,343.03	2,382.41	2,261.35	4,725.44	4,721.73	10,451.67
3	Profit/(loss) before exceptional items and tax (1-2)	(1.49)	62.82	(207.19)	61.35	(187.18)	(964.23)
4	Exceptional items	-	-	-	-	-	(285.94)
5	Profit/(Loss) before tax (3+4)	(1.49)	62.82	(207.19)	61.35	(187.18)	(1,250.17)
6	Tax expense/(income)						
	Current Tax	-	-	(16.55)	-	-	-
	Deferred Tax	18.19	(42.74)	836.34	(24.56)	902.60	718.84
	Tax for earlier years	-	-	4.83	-	4.83	4.83
7	Net Profit/(Loss) for the period (5-6)	(19.67)	105.57	(1,031.81)	85.90	(1,094.61)	(1,973.84)
8	Other comprehensive income						
	-Items that will not be reclassified to profit or loss	-	2.96	1.58	2.96	3.15	11.86
	-Income tax relating to items that will not be reclassified to profit or loss	0.77	(0.77)	(0.41)	-	(0.82)	(3.08)
	Total other comprehensive income	0.77	2.19	1.17	2.96	2.33	8.78
9	Total comprehensive income/ (loss) for the period (7+8)	(18.90)	107.75	(1,030.64)	88.87	(1,092.28)	(1,965.06)
10	Paid-up equity share capital (Face value per share Rs. 10/-)	8,560.40	8,560.40	8,560.40	8,560.40	8,560.40	8,560.40
11	Other Equity						
12	Earnings per equity share (Face value per share Rs. 10/-)						
	Basic (Rs.)	(0.02)	0.12	(1.24)	0.10	(1.36)	(2.37)
	Diluted (Rs.)	(0.02)	0.12	(1.24)	0.10	(1.36)	(2.37)



JHS SVENDGAARD LABORATORIES LIMITED

Registered Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahan, Distt. Sirmour, Himachal Pradesh - 173030, India

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2025

(Rs. in lakhs)



	Particulars	As at 30 September 2025	As at 31 March 2025
		Audited	Audited
A	ASSETS		
	Non-current assets		
	Property, plant and equipment	8,486.37	8,591.85
	Capital work-in-progress	294.50	-
	Right-of-use assets	48.54	112.23
	Goodwill	79.61	79.61
	Intangible assets	217.31	248.90
	Financial Assets		
	(i) Investments	489.21	365.00
	(ii) Loans	75.52	74.21
	(iii) Other Financial Assets	402.59	357.66
	Deferred Tax Assets (net)	354.86	330.31
	Non-current tax assets (net)	120.53	103.40
	Other non-current assets	4,251.83	4,513.40
	Total non-current assets	14,820.88	14,776.56
	Current assets		
	Inventories	1,387.00	1,188.34
	Financial Assets		
	(i) Trade receivables	1,170.02	1,305.91
	(ii) Cash and cash equivalents	1,681.90	672.18
	(iii) Bank balances other than (ii) above	122.56	1,279.79
	(iv) Loans	-	-
	(v) Other Financial Assets	196.61	47.23
	Other current assets	1,347.77	871.04
	Current tax assets (net)	3.56	15.90
	Total current assets	5,909.40	5,380.40
	Total assets	20,730.29	20,156.96
B	EQUITY AND LIABILITIES:		
	Equity		
	Equity Share Capital	8,560.40	8,560.40
	Other Equity	8,844.68	8,752.84
	Total equity	17,405.09	17,313.23
	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	(i) Borrowings	519.95	68.53
	(ii) Lease liabilities	86.94	32.05
	Provisions	145.71	150.57
	Other non-current liabilities	102.11	102.15
	Total non-current liabilities	854.72	373.30
	Current liabilities		
	Financial liabilities		
	(i) Borrowings	451.82	445.74
	(ii) Trade payables		
	- total outstanding dues of micro and small enterprises	348.42	392.22
	- total outstanding dues of creditors other than micro and small enterprises	920.30	951.52
	(iii) Lease Liabilities	-	79.53
	(iv) Other financial liabilities	493.34	480.72
	Other current liabilities	241.16	105.08
	Provisions	15.46	15.61
	Total current liabilities	2,470.49	2,470.43
	Total liabilities	3,325.20	2,843.73
	Total equity and liabilities	20,730.29	20,156.96



JHS Svendgaard Laboratories Limited
Standalone Statement of Cash Flows for the half year ended 30 September 2025
(All amounts are in Indian Rupees lakhs, unless otherwise stated)

Particulars	Year ended 30 September, 2025	Year ended 30 September, 2024
	(Unaudited)	(Unaudited)
A. Cash Flow from Operating Activities		
Profit before tax	61.36	(187.18)
Adjustments for:		
Depreciation and amortization expenses	373.74	395.30
(Profit)/Loss on disposal of property plant and equipment (net)	(9.03)	(2.76)
Interest income	(72.35)	(35.18)
Interest income on Financial asset measured at amortised cost	(9.41)	(2.16)
Government grant amortization	(7.00)	(7.00)
CWIP Written off	-	4.03
TDS receivables written off	-	15.59
Balances and advances written off	(6.47)	0.61
Provision no longer required written back	(62.16)	(24.98)
Bad debts written off	-	-
Provision for doubtful advances	-	34.99
Gratuity and Leave Encashment	6.26	-
Amortisation of deferred rent expense	8.72	2.51
Profit on sale of Mutual fund	(1.37)	(4.74)
Interest and finance Charges	32.70	22.20
Exchange (gain)/loss (net)	(7.95)	(9.60)
Fair value adjustments	(17.91)	(28.49)
Operating profit before working capital changes	289.03	173.05
Adjustments for :		
(Increase)/Decrease in inventories	(198.65)	(70.59)
(Increase)/Decrease in trade receivables	142.37	(192.31)
(Increase)/Decrease in other current assets	(476.73)	51.51
(Increase)/Decrease in other current financial assets	(149.38)	(1.33)
(Increase)/Decrease in other non-current financial assets	(18.38)	17.81
(Increase)/Decrease in other non-current assets	(12.86)	(2.02)
Increase/ (decrease) in other current financial liabilities	60.57	23.72
Increase/ (decrease) in trade payables	(67.09)	(14.41)
Increase/ (decrease) in lease liabilities	-	-
Increase/ (decrease) in other non current liabilities	7.05	(2.60)
Increase/ (decrease) in provisions	(5.34)	11.02
Increase/ (decrease) in other current liabilities	136.08	102.73
Cash generated/(used) from operations	(293.33)	96.58
Taxes paid	(4.79)	(28.73)
Net cash generated/(used) from operating activities	(298.12)	67.85



JHS Svendgaard Laboratories Limited
Standalone Statement of Cash Flows for the half year ended 30 September 2025
(All amounts are in Indian Rupees lakhs, unless otherwise stated)



Particulars	Year ended 30 September, 2025	Year ended 30 September, 2024
	(Unaudited)	(Unaudited)

B. Cash Flow from Investing Activities

Purchase of property plant and equipment	72.33	(520.39)
Capital Work in Progress	(294.50)	(94.38)
Right of Use Assets	33.23	-
Proceeds from sale of Property Plant and Equipment	10.42	4.00
Purchase of mutual funds	-	-
Loan money received back	(1.31)	47.25
Proceeds from Mutual funds	7.50	16.97
Proceeds from sale of investments	(112.42)	0.20
Purchase of investments (Rs. 10/-)	(0.00)	(0.00)
Interest income received	72.35	53.59
Change in other bank balance and cash not available for immediate use	1,140.08	(2,474.53)
Net Cash generated/(used) in investing activities	927.67	(2,967.29)

C. Cash Flow from Financing Activities

Proceeds from/ (repayment of) long term borrowings	451.43	(5.75)
Proceeds from/ (repayment of) short term borrowings	6.08	(56.11)
Repayment of lease liabilities	(44.64)	(35.71)
Proceed from share capital and securities premium	-	2,000.00
Proceed/(utilization) from share warrant	-	250.00
Interest and financial charges	(32.70)	(9.05)
Net increase from financing activities	380.17	2,143.38

Net Increase/(decrease) in cash and cash equivalents	1,009.72	(756.06)
Opening balance of cash and cash equivalents	672.18	886.63
Closing balance of cash and cash equivalents	1,681.90	130.57

Components of cash and cash equivalents as at end of the year

Cash on hand	26.87	54.42
Balances with banks	-	-
- on current account	325.01	76.15
- in term deposits with original maturity of 3 months or less	1,330.02	-
Cash and bank balance	1,681.90	130.57



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2025

Notes:

- 1 The above un-audited consolidated financial results have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 14 November 2025.
- 2 The consolidated financial results have been prepared in accordance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013, other accounting principles generally accepted in India and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The consolidated financials results of the Group include financial results of a Wholly -Owned subsidiary namely JHS Svendgaard Mechanical and Warehouse Private Limited. The details of ownership is given as below :-

Particulars	As on 31 March, 2025	As on 31 March, 2024
JHS Svendgaard Mechanical and Warehouse Private Limited	100.00%	99.99%

- 4 The Company is in the business of manufacturing of oral care products and hence has only one reportable operating segment as per Ind AS 108 – Operating Segments.
- 5 In compliance with section 42 and 62 of the Companies Act, 2013 & rules made thereunder and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and pursuant to the resolution of Board of Directors dated 4th June 2024 and of shareholders by special resolution dated 4th July 2024, the Holding Company on 3rd August 2024 has allotted on preferential allotment basis:
 - a) 72,07,204 equity shares of face value of Rs. 10 each at an issue price of Rs. 27.75 per equity share (including premium of Rs. 17.75 per equity share) aggregating to Rs. 2000 lakhs to individuals belonging to "Non-Promoter" Category; and
 - b) 36,03,602 fully convertible warrants of Rs. 10 each at an issue price of Rs. 27.75 per warrant (including premium of Rs. 17.75 per warrant) aggregating to Rs. 1000 lakhs to individuals belonging to "Promoter & Promoter Group" and "Non-Promoter" Categories on payment of 25% of issue price per warrant. Each warrant shall carry right of being convertible into fully paid up equity shares of face value of Rs. 10 each within a period of eighteen months from the date of allotment of warrants on payment of balance amount of 75% of issue price.

Further, out of the amount of Rs. 2000 lakhs received against aforesaid issue of shares and Rs. 250 lakhs against the issue of warrants, for the quarter ended 30th september 2025, the company has utilized the money for project in Jammu and Kashmir - Rs.71.29 lakhs, General Corporate Purpose - Rs.749.50 lakhs, Capital Expenditure - Rs.229.62 lakhs and balance Rs.1200.60 lakhs has been parked in fixed deposits, pending utilisation.
- 6 Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification or also in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1 April 2021.

For and on behalf of Board of Directors

Place: New Delhi
Date: 14 November 2025

Nikhil Nanda
Managing Director
DIN : 00051501



Memb No. 095943

UDIN :- 25095943BMJJRW4453



Independent Auditor's Review Report on Consolidated Unaudited Financial Results and Year to Date Financial Results of JHS Svendgaard Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results ('the Statement') of JHS Svendgaard Laboratories Limited ('the Holding Company') and its wholly owned subsidiary (the Holding Company and its subsidiary together referred to as "the Group"), for the **quarter ended 30 September 2025 and year to date financial results for the period 01 April 2025 to 30 September 2025** being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The statement includes the results of the following entity: -

S.No.	Name of Entity	Relationship
1.	JHS Svendgaard Mechanical and Warehouse Private Limited	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 7(a) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed, as



accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **Emphasis of Matter**

There is no Emphasis of Matter in the report for the quarter ended September 30, 2025.

7. **Other Matters**


- a) We did not review the interim unaudited financial information of the wholly owned subsidiary included in the Statement, whose financial information reflects total revenues of Rs. Nil lakhs, total net profit/ (loss) after tax of Rs (0.17 lakhs), and total comprehensive income/ (loss) of Rs. (0.17 Lakhs), for the quarter ended 30 September 2025 and year to date financial results for the period 01 April 2025 to 30 September 2025 as considered in the Statement. This interim unaudited financial information has been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of the wholly owned subsidiary is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

- b) The consolidated financial results/statements for the quarter and half year ended September 30, 2024 presented in the accompanying standalone financial results were reviewed by the predecessor auditor who expressed unmodified opinion vide their report dated November 13, 2024. The aforesaid financial information/ results/ statements were furnished to us by the management and has been relied upon for the purpose of review of accompanying statement.

Our conclusion is not modified in respect of above matters.

For V.K. Khosla & Co.
Chartered Accountants
FRN 002283N


Amit Khosla
(Partner)

Memb No. 095943

UDIN: 25095943 BMJRW4453



Place: New Delhi

Date: November 14, 2025

JHS SVENDGAARD LABORATORIES LIMITED
Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil-Nahan, Distt. Sirmour, Himachal Pradesh - 173030, India
CIN-L74110HP2004PLC027558

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(Rs. in lakhs)

S.No.	Particulars	Quarter Ended 30 September 2025	Quarter Ended 30 Jun 2025	Quarter Ended 30 September 2024	Half Year Ended 30 September 2025	Half Year Ended 30 September 2024	Year Ended 31 March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Revenue from operations	2,227.71	2,345.41	1,968.07	4,573.12	4,416.46	9,199.73
	Other income	113.84	99.83	86.09	213.67	118.09	287.71
	Total income	2,341.56	2,445.24	2,054.16	4,786.80	4,534.55	9,487.44
2	Expenses						
	Cost of materials consumed	1,294.62	1,421.83	1,239.20	2,716.45	2,718.05	5,745.75
	Purchases of stock-in-trade	85.78	9.72	20.33	95.50	112.72	308.19
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(66.48)	(41.64)	53.84	-108.12	-83.65	50.28
	Employee benefits expense	269.01	266.53	264.81	535.54	516.50	1,011.63
	Finance costs	20.09	15.67	10.52	35.76	22.20	56.50
	Depreciation and amortisation expenses	186.13	181.61	198.07	373.74	195.30	795.02
	Other expenses	554.00	521.75	474.70	1,076.75	1,040.84	2,484.89
	Total expenses	2,313.14	2,388.16	2,261.47	4,725.61	4,721.96	10,452.25
3	Profit/(loss) before exceptional items and tax (1-2)	(1.59)	62.78	(207.31)	61.19	(187.41)	(964.81)
4	Exceptional items	-	-	-	-	-	(285.94)
5	Profit/(Loss) before tax (3+4)	(1.59)	62.78	(207.31)	61.19	(187.41)	(1,250.76)
6	Tax expense/(income)						
	Current Tax	-	-	(16.55)	-	-	-
	Deferred Tax	18.18	(42.74)	836.34	(24.50)	502.60	718.84
	Tax for earlier years	-	-	4.83	-	4.83	4.83
7	Net Profit/(Loss) for the period (5+6)	(19.77)	105.52	(1,031.93)	85.74	(1,094.84)	(1,974.43)
8	Other comprehensive income						
	- Items that will not be reclassified to profit or loss	0.00	2.96	1.58	2.96	3.15	11.86
	- Income tax relating to items that will not be reclassified to profit or loss	0.77	(0.77)	(0.41)	-	-0.82	(3.08)
	Total other comprehensive income	0.77	2.19	1.17	2.96	2.33	8.78
9	Total comprehensive income/ (loss) for the period (7+8)	(18.99)	107.72	(1,030.76)	88.71	(1,092.51)	(1,965.66)
	Net profit attributable to:						
	Owners of the Company	(19.77)	105.52	(1,031.93)	85.74	(1,094.84)	(1,974.43)
	Non-controlling interest	-	-	-	-	-	-
	Other Comprehensive Income attributable to:						
	Owners of the Company	0.77	2.19	1.17	2.96	2.33	8.78
	Non-controlling interest	-	-	-	-	-	-
	Total Comprehensive Income attributable to:						
	Owners of the Company	(18.99)	107.72	(1,030.76)	88.71	(1,092.51)	(1,965.65)
	Non-controlling interest	-	-	-	-	-	-
10	Paid-up equity share capital (Face value per share Rs. 10/-)	8,560.40	8,560.40	8,560.40	8,560.40	8,560.40	8,560.40
11	Other Equity						
12	Earnings per equity share (Face value per share Rs. 10/-)						
	Basic (Rs.)	(0.02)	0.12	(1.24)	0.10	(1.36)	(2.37)
	Diluted (Rs.)	(0.02)	0.12	(1.24)	0.10	(1.36)	(2.37)



JHS SVENDGAARD LABORATORIES LIMITED

Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahan, Distt. Sirmour, Himachal Pradesh - 173030, India

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2025

(Rs. in lakhs)

	Particulars	As at 30 September 2025	As at 31 March 2025
		Audited	Audited
A	ASSETS		
	Non-current assets		
	Property, plant and equipment	8,486.37	8,591.85
	Capital work-in-progress	294.50	0.00
	Right-of-use assets	48.54	112.23
	Goodwill	79.61	79.61
	Intangible assets	217.31	248.90
	Financial Assets		
	(i) Investments	488.21	364.00
	(ii) Loans	75.52	74.21
	(iii) Other Financial Assets	402.79	357.85
	Deferred Tax Assets (net)	354.86	330.31
	Non-current tax assets (net)	120.53	103.40
	Other non-current assets	4,210.15	4,471.72
	Total non-current assets	14,778.39	14,734.08
	Current assets		
	Inventories	1,387.00	1,188.34
	Financial Assets		
	(i) Trade receivables	1,170.02	1,305.91
	(ii) Cash and cash equivalents	1,683.86	674.54
	(iii) Bank balances other than (ii) above	122.56	1,279.79
	(iv) Loans	0.00	-
	(v) Other Financial Assets	196.61	47.23
	Other current assets	1,347.77	871.04
	Current tax assets (net)	3.56	15.90
	Total current assets	5,911.36	5,382.75
	Total assets	20,689.74	20,116.83
B	EQUITY AND LIABILITIES:		
	Equity		
	Equity Share Capital	8,560.40	8,560.40
	Other Equity	8,804.02	8,712.32
	Total equity	17,364.42	17,272.72
	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	(i) Borrowings	519.95	68.53
	(ii) Lease liabilities	86.94	52.05
	Provisions	145.71	150.57
	Other non-current liabilities	102.11	102.15
	Total non-current liabilities	854.72	373.30
	Current liabilities		
	Financial liabilities		
	(i) Borrowings	451.82	445.74
	(ii) Trade payables		
	- total outstanding dues of micro and small enterprises	348.42	392.22
	- total outstanding dues of creditors other than micro and small enterprises	920.43	951.92
	(iii) Lease Liabilities	-	79.53
	(iv) Other financial liabilities	493.34	480.72
	Other current liabilities	241.15	105.07
	Provisions	15.46	15.61
	Total current liabilities	2,470.60	2,470.81
	Total liabilities	3,325.32	2,844.11
	Total equity and liabilities	20,689.74	20,116.83



JHS Svendgaard Laboratories Limited
Consolidated Statement of Cash Flows for the half year ended 30 September 2025
(All amounts are in Indian Rupees lakhs, unless otherwise stated)

Particulars	Year ended 30 September, 2025	Year ended 30 September, 2024
	(Unaudited)	(Unaudited)
A. Cash Flow from Operating Activities		
Profit before tax	61.18	(187.41)
Adjustments for:		
Depreciation and amortization expenses	373.74	395.30
(Profit)/Loss on disposal of property plant and equipment (net)	(9.03)	(2.76)
Interest income	(72.35)	(35.18)
Interest income on Financial asset measured at amortised cost	(9.41)	(2.16)
Government grant amortization	(7.09)	(7.09)
CWIP Written off	-	4.03
TDS receivables written off	-	15.59
Balances and advances written off	(6.47)	0.61
Provision no longer required written back	(62.16)	(24.98)
Bad debts written off	-	-
Provision for doubtful advances	-	34.99
Gratuity and Leave Encashment	6.26	-
Amortisation of deferred rent expense	8.72	2.51
Profit on sale of Mutual fund	(1.37)	(4.74)
Interest and finance Charges	32.70	22.20
Exchange (gain)/loss (net)	(7.95)	(9.60)
Fair value adjustments	(17.91)	(28.49)
Operating profit before working capital changes	288.86	172.82
Adjustments for :		
(Increase)/Decrease in inventories	(198.65)	(70.59)
(Increase)/Decrease in trade receivables	142.37	(192.31)
(Increase)/Decrease in other current assets	(476.73)	51.51
(Increase)/Decrease in other current financial assets *	(149.38)	(1.33)
(Increase)/Decrease in other non-current financial assets	(18.38)	17.81
(Increase)/Decrease in other non-current assets	(12.83)	(1,480.65)
Increase/ (decrease) in other current financial liabilities	60.57	23.51
Increase/ (decrease) in trade payables	(67.09)	(14.41)
Increase/ (decrease) in lease liabilities	-	-
Increase/ (decrease) in other non current liabilities	7.05	1,472.02
Increase/ (decrease) in provisions	(5.34)	11.02
Increase/ (decrease) in other current liabilities	135.83	102.73
Cash generated/(used) from operations	(293.74)	92.13
Taxes paid	(4.79)	(28.73)
Net cash generated/(used) from operating activities	(298.53)	63.40



JHS Svendgaard Laboratories Limited
Consolidated Statement of Cash Flows for the half year ended 30 September 2025
(All amounts are in Indian Rupees lakhs, unless otherwise stated)

Particulars	Year ended 30 September, 2025	Year ended 30 September, 2024
	(Unaudited)	(Unaudited)
B. Cash Flow from Investing Activities		
Purchase of property plant and equipment	72.33	(517.38)
Capital Work in Progress	(294.50)	(94.38)
Right of Use Assets	33.23	-
Proceeds from sale of Property Plant and Equipment	10.42	4.00
Purchase of mutual funds	-	-
Loan money received back	(1.31)	47.25
Proceeds from Mutual funds	7.50	16.97
Proceeds from sale of investments	(112.42)	0.20
Purchase of Investments (Rs. 10/-)	(0.00)	(0.00)
Interest income received	72.34	13.59
Change in other bank balance and cash not available for immediate use	1,140.08	(2,474.53)
Net Cash generated/(used) in investing activities	927.66	(2,984.28)
C. Cash Flow from Financing Activities		
Proceeds from/ (repayment of) long term borrowings	451.43	(5.75)
Proceeds from/ (repayment of) short term borrowings	6.08	(56.11)
Repayment of lease liabilities	(44.64)	(35.71)
Proceed from share capital and securities premium	-	2,000.00
Proceed/(utilization) from share warrant	-	250.00
Interest and financial charges	(32.70)	(9.05)
Net increase from financing activities	380.18	2,143.38
Net Increase/(decrease) in cash and cash equivalents	1,009.31	(777.50)
Opening balance of cash and cash equivalents	674.55	910.47
Closing balance of cash and cash equivalents	1,683.86	132.97
Components of cash and cash equivalents as at end of the year		
Cash on hand	26.92	54.43
Balances with banks		-
- on current account	326.92	78.54
- in term deposits with original maturity of 3 months or less	1,330.02	-
Cash and bank balance	1,683.86	132.97





JHS SVENDGAARD LABORATORIES LIMITED

Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahan, Distt. Sirmour, Himachal Pradesh - 173030, India

CIN-L74110HP2004PLC027558

CIN-L74110HP2004PLC027558

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2025

Notes:

- 1 The above unaudited standalone financial results have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 14 November 2025.
- 2 The standalone results have been prepared in accordance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013, other accounting principles generally accepted in India and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The Company is in the business of manufacturing of oral care products and hence has only one reportable operating segment as per Ind AS 108 - Operating Segments.
- 4 In compliance with section 42 and 62 of the Companies Act, 2013 & rules made thereunder and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and pursuant to the resolution of Board of Directors dated 4th June 2024 and of shareholders by special resolution dated 4th July 2024, the Company on 3rd August 2024 has been allotted on preferential allotment basis:

- a) 72,07,204 equity shares of face value of Rs. 10 each at an issue price of Rs. 27.75 per equity share (including premium of Rs. 17.75 per equity share) aggregating to Rs. 2000 lakhs to individuals belonging to "Non-Promoter" Category; and
- b) 36,03,602 fully convertible warrants of Rs. 10 each at an issue price of Rs. 27.75 per warrant (including premium of Rs. 17.75 per warrant) aggregating to Rs. 1000 lakhs to individuals belonging to "Promoter & Promoter Group" and "Non-Promoter" Categories on payment of 25% of issue price per warrant. Each warrant shall carry right of being convertible into fully paid up equity shares of face value of Rs. 10 each within a period of eighteen months from the date of allotment of warrants on payment of balance amount of 75% of issue price.

Further, out of the amount of Rs. 2000 lakhs received against aforesaid issue of shares and Rs. 250 lakhs against the issue of warrants, for the quarter ended 30th September 2025, the company has utilized the money for project in Jammu and Kashmir - Rs.71.29 lakhs, General Corporate Purpose - Rs.749.50 lakhs, Capital Expenditure - Rs.229.62 lakhs and balance Rs.1200.60 lakhs has been parked in fixed deposits, pending utilisation.

- 5 Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification or also in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1 April 2021.

For and on behalf of Board of Directors



Nikhil Nanda
Managing Director
DIN : 00051501

Place: New Delhi

Date: 14 November 2025



Memb. No. 095943
UDIN : 2509594381111 RV7823